Symbiotec Pharmalab Limited has submitted a regulatory disclosure intimating about an upcoming earnings conference call for analysts and investors. The disclosure is made pursuant to Regulation 30 read with Para A of Schedule III and Regulation 46(2) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
The earnings conference call is scheduled to discuss the financial performance and business updates for the quarter ended June 30, 2026 (Q1FY27). The call will be held on Tuesday, September 22, 2026, at 10:00 A.M. IST through virtual/audio conference format.
JM Financial Institutional Securities Limited is hosting the conference call. The company has enclosed a detailed invitation containing conference call particulars with this disclosure.
The schedule of the call is subject to change due to exigencies, if any. The company explicitly states that no unpublished price sensitive information shall be shared during the call.
This information is also being made available on the company's website at investor.symbiotec.com.
The document includes a safe harbor statement noting that the management discussion may include forward-looking statements subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those contemplated.
The document was signed by Salil Jain, Company Secretary & Compliance Officer, on September 17, 2026, at 18:40:29 IST.